Syngene's Q1 FY27 revenue dropped 16% to 736 Cr, with EBITDA down 56% to 91 Cr, impacted by lower biologics client offtake and forex loss.

The company expects H1 degrowth, H2 improvement, aiming for single-digit revenue degrowth for the full year.

Kiran Mazumdar-Shaw is the new Executive Chairperson, focusing on CDMO, AI, and efficiency.